Publications
Detailed Information
Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Paeng, Jin Chul | - |
dc.contributor.author | Chun, In Kook | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Lee, Dong Soo | - |
dc.contributor.author | Kim, Chul Woo | - |
dc.contributor.author | Chung, June-Key | - |
dc.contributor.author | Kim, Il Han | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2020-04-27T11:30:15Z | - |
dc.date.available | 2020-04-27T11:30:15Z | - |
dc.date.created | 2020-02-19 | - |
dc.date.issued | 2013-03 | - |
dc.identifier.citation | Cancer, Vol.119 No.6, pp.1195-1202 | - |
dc.identifier.issn | 0008-543X | - |
dc.identifier.other | 91793 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165466 | - |
dc.description.abstract | BACKGROUND: This study was undertaken to evaluate the prognostic value of quantitative metabolic parameters in [18F]2-fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET) for diffuse large B cell lymphoma (DLBCL). METHODS: A total of 140 DLBCL patients underwent FDG-PET scans before rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy. The maximal standardized uptake value (SUVmax) and total lesion glycolysis (TLG) were calculated, with the margin thresholds as 25%, 50%, and 75% of SUVmax of all lesions. Treatment outcomes were compared between groups according to metabolic parameters and the International Prognostic Index (IPI). RESULTS: After a median follow-up of 28.5 months (range, 5-81 months), the 2-year progression-free survival (PFS) and overall survival (OS) were 83% and 87%, respectively. Among metabolic parameters, TLG at the threshold of 50% (TLG50) was significantly associated with treatment outcomes. High TLG50 values (>415.5) were associated with reduced survivals compared with low TLG50 values (415.5) (2-year PFS of 73% versus 92%, P = .007; and 2-year OS of 81% versus 93%, P = .031). High IPI score (3) significantly reduced OS (2-year OS of 79% versus 90%, P = .049). Ann Arbor stage III/IV adversely affected PFS (P = .013). However, high IPI score and Ann Arbor stage of III/V did not significantly shorten PFS (P = .200) and OS (P = .921), respectively. High TLG50 values independently predicted survivals by multivariate analysis (hazard ratio = 4.4; 95% confidence interval = 1.5-13.1; P = .008 for PFS and hazard ratio = 3.1; 95% confidence interval = 1.0-9.6; P = .049 for OS). CONCLUSIONS: Combined assessment of volume and metabolism (ie, TLG) is predictive of survivals in DLBCL patients who are treated with R-CHOP. Cancer 2013. (c) 2012 American Cancer Society. | - |
dc.language | 영어 | - |
dc.publisher | John Wiley & Sons Inc. | - |
dc.title | Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 정준기 | - |
dc.contributor.AlternativeAuthor | 김일한 | - |
dc.contributor.AlternativeAuthor | 김철우 | - |
dc.contributor.AlternativeAuthor | 전윤경 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 이동수 | - |
dc.identifier.doi | 10.1002/cncr.27855 | - |
dc.citation.journaltitle | Cancer | - |
dc.identifier.wosid | 000315696600013 | - |
dc.identifier.scopusid | 2-s2.0-84874693336 | - |
dc.citation.endpage | 1202 | - |
dc.citation.number | 6 | - |
dc.citation.startpage | 1195 | - |
dc.citation.volume | 119 | - |
dc.identifier.sci | 000315696600013 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Jeon, Yoon Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Lee, Dong Soo | - |
dc.contributor.affiliatedAuthor | Kim, Chul Woo | - |
dc.contributor.affiliatedAuthor | Chung, June-Key | - |
dc.contributor.affiliatedAuthor | Kim, Il Han | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | NON-HODGKINS-LYMPHOMA | - |
dc.subject.keywordPlus | F-18-FDG PET/CT | - |
dc.subject.keywordPlus | R-CHOP | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | RITUXIMAB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | MODELS | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | diffuse large B cell lymphoma | - |
dc.subject.keywordAuthor | positron emission tomography | - |
dc.subject.keywordAuthor | total lesion glycolysis | - |
dc.subject.keywordAuthor | Ann Arbor stage | - |
dc.subject.keywordAuthor | International Prognostic Index | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.